Smith Karen Lisa, Dang Chau, Seidman Andrew D
Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Expert Opin Drug Saf. 2006 Sep;5(5):619-29. doi: 10.1517/14740338.5.5.619.
The HER2/neu gene is amplified in approximately 25% of breast cancers, leading to HER2 protein overexpression and shortened overall survival and time to relapse. Trastuzumab is a humanised, monoclonal antibody against HER2, which improves survival for women with metastatic HER2-overexpressing breast cancer and reduces the risk of recurrence in women with early stage HER2-overexpressing breast cancer. Cardiac toxicity was an unexpected finding in the pivotal Phase III trial leading to the approval of trastuzumab, and prospective cardiac monitoring has, therefore, been incorporated into more recent clinical trials of trastuzumab. This article reviews the cardiac toxicity findings in key trastuzumab clinical trials and clinical characteristics of trastuzumab-associated cardiac toxicity.
HER2/neu基因在约25%的乳腺癌中发生扩增，导致HER2蛋白过度表达，并缩短总生存期和复发时间。曲妥珠单抗是一种针对HER2的人源化单克隆抗体，可改善转移性HER2过表达乳腺癌女性的生存期，并降低早期HER2过表达乳腺癌女性的复发风险。在导致曲妥珠单抗获批的关键III期试验中，心脏毒性是一个意外发现，因此，前瞻性心脏监测已被纳入曲妥珠单抗的更多近期临床试验中。本文综述了曲妥珠单抗关键临床试验中的心脏毒性发现以及曲妥珠单抗相关心脏毒性的临床特征。
